President Donald Trump turned his attention to the Keystone XL Pipeline on Monday evening, calling for the company building it to "come back to America, and get it built — NOW!" Trump said he ...
Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat ...
Analysts project peak sales of $1.7 billion, although the path to reaching this figure may be gradual. Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential ...
A month after Biogen signaled plans to shift its attention to “external opportunities,” it delivered on that ambition. … ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal Vandana Singh Tue, Feb 18, 2025, 1:32 PM 2 min read ...
Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...
On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果